Meyka Pro is live. Get 50% off your first 3 months.Get Started →
Meyka Pro banner
Vericel Corporation

Vericel Corporation (VCEL) Stock Overview

Explore Vericel Corporation’s financial performance, market position, analyst ratings, and future outlook.

VCEL●NASDAQ
HealthcareBiotechnology
$39.55
$0.47(1.17%)
U.S. Market opens in 13h 11m

Vericel Corporation (VCEL)

Meyka AI Score

Z

Key Financials

Market Cap2B
P/E Ratio82.20
EPS (TTM)$0.47
ROE0.07%
Fundamental Analysis

AI Price Forecasts

1 Month$39.07
3 Months$57.72
1 Year Target$42.31

VCEL Stock Analysis & Investment Overview (NASDAQ)

Our AI-powered analysis of Vericel Corporation (NASDAQ: VCEL) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of B+, Vericel Corporation's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.

The current technical analysis of VCEL on the NASDAQ shows an RSI of 40.08, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $42.31 for the NASDAQ listing.

Key metrics behind Vericel Corporation's NASDAQ-traded stock include a P/E ratio of 82.20 and a market capitalization of 2B. Combined with our AI analysis, these give both institutional and retail investors a clear view of VCEL on the NASDAQ.

Price Performance (NASDAQ: VCEL)

1-Day Change
-1.17%
5-Day Change
-0.45%
1-Month Change
-7.33%
3-Month Change
-2.27%
6-Month Change
25.92%
Year-to-Date (YTD) Change
9.83%
1-Year Change
24.33%
3-Year Change
15.68%
5-Year Change
-17.95%
All-Time (Max) Change
-96.47%

Contact Information

https://vcel.com
617 588 5555
25 Blue Sky Drive, Burlington, MA, 01803

Company Facts

3,980 Employees
IPO DateFeb 4, 1997
CountryUS
Actively Trading

Frequently Asked Questions